The evolving role of cetuximab in non-small cell lung cancer

Clinical Cancer Research

Volumn 12, Issue 14, 2006, Pages

  Lilenbaum, Rogerio C ^a   Johnson, Bruce ^b   Lynch, Thomas ^b   Sandler, Alan ^b   Bunn, Paul ^b   Adjei, Alex ^b   Johnson, David ^b   Goss, Glenwood ^b  

^a Mount Sinai Cancer Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; NAVELBINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RASH; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33746896572     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0097     Document Type: Conference Paper

References (17)

1. Mendelsohn J. Epidermal growth factor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997;3:2703-7.
2. Raben D, Helfrich B, Chan DC, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005;11:795-805.
3. Cunningham D, Humblet Y, Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
4. Bonner JA, Giralt J, Harari M. Cetuximab prolongs survival in patients with loc-regionally advanced squamous cell carcinoma of head and neck: a phase III study of high-dose radiation therapy with or without cetuximab. Proc Am Soc Clin Oncol 2004;23: abstr 5507.
5. Kim ES, Mauer AM, Tran HT, et al. A phase II of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2003;22:642.
6. Lilenbaum R, Bonomi P, Ansari R, et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer. Final results. Proc Am Soc Clin Oncol 2005;23: abstr 7036.
7. Kelly K, Hanna N, Rosenberg A, et al. Multicenter phase II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol 2003;22:644.
8. Robert F, Blumenschein K, Dicke T, et al. Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer [abstract 2587]. Proc Am Soc Clin Oncol 2003;22:643.
9. Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) versus CV alone I the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2004;23: abstr 7012.
10. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
11. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-94.
12. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-84.
13. Gatzemeier U. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;22:7010.
14. Bier H, Hoffmann T, Haas I, et al. Anti-epidermal growth factor receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 1998;46:167-73.
15. Johnson B, Janne P. Selecting patients for epidermal growth factor receptor inhibitor treatment: a FISH story or a tale of mutations? J Clin Oncol 2005;23:6813-6
16. Raez L, Lopes G, Lilenbaum R. Clinical responses to gefitinib after failure of treatment with cetuximab in advanced non-small cell lung cancer. J Clin Oncol 2005;23:4244-5.
17. Mukohara T, Engelman JA, Hanna N, et al. Differential effects of gefitinib and cetuximab on non-small cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005;97:1185-94.